Delving into the Latest Updates on 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Jiangsu Kunli Biomedicine) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesNervous System DiseasesRespiratory Diseases+ [1]

Active Indication

BacteremiaMeningitisPneumonia, Bacterial

Inactive Indication

Pneumococcal Infections

Originator Organization

Shandong Kunli Biopharmaceutical Co., Ltd.

Jiangsu Kunli Biopharmaceutical Co., Ltd.

Active Organization

Jiangsu Kunli Biopharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

[Translation] A phase I clinical trial to evaluate the safety and tolerability of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 18 years and above, and a phase II clinical trial to evaluate the safety and immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 65 years and above

Ⅰ期：评价24价肺炎球菌多糖结合疫苗在18周岁及以上人群中接种的安全性和耐受性。Ⅱ期：评价24价肺炎球菌多糖结合疫苗在65周岁及以上人群中接种的安全性和免疫原性。

[Translation]

Phase I: To evaluate the safety and tolerability of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 18 years and above. Phase II: To evaluate the safety and immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 65 years and above.

Start Date27 Feb 2022

Sponsor / Collaborator

Jiangsu Kunli Biopharmaceutical Co., Ltd.

[+1]

NL-OMON26136

/ CompletedNot ApplicableIIT

Immunogenicity of alternative and reduced immunization schedules using the thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae.

Start Date24 May 2010

Sponsor / Collaborator-

EUCTR2009-014315-12-NL

/ Not yet recruitingNot ApplicableIIT

Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae - Pneumococcal vaccination: reduced and different schedule

Start Date08 Apr 2010

Sponsor / Collaborator-

100 Clinical Results associated with 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Jiangsu Kunli Biomedicine)

Login to view more data

100 Translational Medicine associated with 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Jiangsu Kunli Biomedicine)

Login to view more data

100 Patents (Medical) associated with 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Jiangsu Kunli Biomedicine)

Login to view more data

100 Deals associated with 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Jiangsu Kunli Biomedicine)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacteremia	Phase 2	China	Jiangsu Kunli Biopharmaceutical Co., Ltd.	27 Feb 2022
Meningitis	Phase 2	China	Jiangsu Kunli Biopharmaceutical Co., Ltd.	27 Feb 2022
Pneumonia, Bacterial	Phase 2	China	Jiangsu Kunli Biopharmaceutical Co., Ltd.	27 Feb 2022
Pneumococcal Infections	Phase 1	China	Jiangsu Kunli Biopharmaceutical Co., Ltd.	10 Jun 2021